WO2000066736A1 - Homologue du facteur de croissance zvegf4 - Google Patents

Homologue du facteur de croissance zvegf4 Download PDF

Info

Publication number
WO2000066736A1
WO2000066736A1 PCT/US2000/040047 US0040047W WO0066736A1 WO 2000066736 A1 WO2000066736 A1 WO 2000066736A1 US 0040047 W US0040047 W US 0040047W WO 0066736 A1 WO0066736 A1 WO 0066736A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
residues
polypeptide
zvegf4
protein
Prior art date
Application number
PCT/US2000/040047
Other languages
English (en)
Other versions
WO2000066736B1 (fr
Inventor
Teresa Gilbert
Charles E. Hart
Paul O. Sheppard
Debra G. Gilbertson
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Priority to AU47145/00A priority Critical patent/AU4714500A/en
Priority to CA2370948A priority patent/CA2370948C/fr
Priority to EP00928993A priority patent/EP1177293A1/fr
Priority to JP2000615760A priority patent/JP2002542825A/ja
Priority to MXPA01011158A priority patent/MXPA01011158A/es
Publication of WO2000066736A1 publication Critical patent/WO2000066736A1/fr
Publication of WO2000066736B1 publication Critical patent/WO2000066736B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)

Abstract

L'invention concerne des facteurs de croissance polypeptidiques, des procédés de fabrication correspondants, des polynucléotides les codant, leurs anticorps et des procédés pour les utiliser. Ces polypeptides comprennent un segment d'acides aminés qui est identique pour au moins 70 % aux résidus 52-179 de SEQ ID NO:2 ou aux résidus 258-370 de SEQ ID NO:2. L'invention concerne aussi des multimères de ces polypeptides. Les polypeptides, les protéines multimères et les polynucléotides peuvent être utilisés dans l'étude et la régulation du développement des tissus et des cellules, en tant que composants du milieu de culture des cellules et comme agents diagnostiques.
PCT/US2000/040047 1999-05-03 2000-05-03 Homologue du facteur de croissance zvegf4 WO2000066736A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU47145/00A AU4714500A (en) 1999-05-03 2000-05-03 Growth factor homolog zvegf4
CA2370948A CA2370948C (fr) 1999-05-03 2000-05-03 Homologue du facteur de croissance zvegf4
EP00928993A EP1177293A1 (fr) 1999-05-03 2000-05-03 Homologue du facteur de croissance zvegf4
JP2000615760A JP2002542825A (ja) 1999-05-03 2000-05-03 増殖因子同族体ｚｖｅｇｆ４
MXPA01011158A MXPA01011158A (es) 1999-05-03 2000-05-03 Factor de crecimiento homologo zvegf4.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30421699A 1999-05-03 1999-05-03
US16446399P 1999-11-10 1999-11-10
US18016900P 2000-02-04 2000-02-04
US60/164,463 2000-02-04
US09/304,216 2000-02-04
US60/180,169 2000-02-04

Publications (2)

Publication Number Publication Date
WO2000066736A1 true WO2000066736A1 (fr) 2000-11-09
WO2000066736B1 WO2000066736B1 (fr) 2000-12-21

Family

ID=27389018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/040047 WO2000066736A1 (fr) 1999-05-03 2000-05-03 Homologue du facteur de croissance zvegf4

Country Status (6)

Country Link
EP (1) EP1177293A1 (fr)
JP (1) JP2002542825A (fr)
AU (1) AU4714500A (fr)
CA (1) CA2370948C (fr)
MX (1) MXPA01011158A (fr)
WO (1) WO2000066736A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025437A2 (fr) * 1999-10-07 2001-04-12 Curagen Corporation Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers
EP1129110A1 (fr) * 1998-11-10 2001-09-05 Ludwig Institute For Cancer Research Facteur de croissance d d'origine plaquettaire, l'adn codant pour celui-ci, et ses utilisations
WO2001089450A2 (fr) * 2000-05-19 2001-11-29 Eli Lilly And Company Traitement de pathologies musculosquelettiques par le polypeptide lp85 et des analogues de celui-ci
US6455283B1 (en) 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
EP1483298A2 (fr) * 2002-02-11 2004-12-08 ZymoGenetics, Inc. Materiaux et procedes pour la preparation de facteurs de croissance dimeres
US7105481B2 (en) 1998-11-10 2006-09-12 Ludwig Institute For Cancer Research Method for stimulating connective tissue growth or wound healing
US7148037B2 (en) 1998-11-10 2006-12-12 Ludwig Institute For Cancer Research Platelet-derived growth factor D, DNA coding therefor, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024811A2 (fr) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Facteur de croissance endotheliale vasculaire
WO1999037671A1 (fr) * 1998-01-27 1999-07-29 Eli Lilly And Company Gene et proteine associes au facteur de croissance des cellules endotheliales vasculaires
WO2000034474A2 (fr) * 1998-12-07 2000-06-15 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349951A1 (fr) * 1998-11-10 2000-05-18 Ludwig Institute For Cancer Research Facteur de croissance d d'origine plaquettaire, l'adn codant pour celui-ci, et ses utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024811A2 (fr) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Facteur de croissance endotheliale vasculaire
WO1999037671A1 (fr) * 1998-01-27 1999-07-29 Eli Lilly And Company Gene et proteine associes au facteur de croissance des cellules endotheliales vasculaires
WO2000034474A2 (fr) * 1998-12-07 2000-06-15 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 15 August 1997 (1997-08-15), STRAUSBERG R.: "EST; H. sapiens cDNA clone IMAGE:824754", XP002144644 *
See also references of EP1177293A1 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7494977B2 (en) 1998-03-17 2009-02-24 Genentech, Inc. Polypeptides homologous to VEGF and BMP1
US6455283B1 (en) 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
US6620784B1 (en) 1998-03-17 2003-09-16 Genentech, Inc. Uses of VEGF-E
US7575879B2 (en) 1998-03-17 2009-08-18 Genentech, Inc. Polypeptides homologous to VEGF and BMP1
US7371377B2 (en) 1998-03-17 2008-05-13 Genentech, Inc. Antibodies to polypeptides homologous to VEGF and BMP1
EP1129110A1 (fr) * 1998-11-10 2001-09-05 Ludwig Institute For Cancer Research Facteur de croissance d d'origine plaquettaire, l'adn codant pour celui-ci, et ses utilisations
US7105481B2 (en) 1998-11-10 2006-09-12 Ludwig Institute For Cancer Research Method for stimulating connective tissue growth or wound healing
US7148037B2 (en) 1998-11-10 2006-12-12 Ludwig Institute For Cancer Research Platelet-derived growth factor D, DNA coding therefor, and uses thereof
EP2151454A3 (fr) * 1998-11-10 2010-02-17 Ludwig Institute For Cancer Research Facteur de croissance D d'origine plaquettaire, l'ADN codant pour celui-ci et ses utilisations
EP1129110A4 (fr) * 1998-11-10 2004-08-04 Ludwig Inst Cancer Res Facteur de croissance d d'origine plaquettaire, l'adn codant pour celui-ci, et ses utilisations
US8834879B2 (en) 1999-05-03 2014-09-16 Zymogenetics, Inc. Methods of treating fibroproliferative disorders of the kidney or reducing kidney fibrosis
US7172757B2 (en) 1999-05-03 2007-02-06 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US7722870B2 (en) 1999-05-03 2010-05-25 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US8298534B2 (en) 1999-05-03 2012-10-30 Zymogenetics, Inc. Method of treating fibrproliferative disorders
US8431129B2 (en) 1999-05-03 2013-04-30 Zymogenetics, Inc. Method of treating fibroproliferative disorders of the heart and lung
WO2001025437A2 (fr) * 1999-10-07 2001-04-12 Curagen Corporation Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers
WO2001025437A3 (fr) * 1999-10-07 2002-04-18 Curagen Corp Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers
WO2001089450A2 (fr) * 2000-05-19 2001-11-29 Eli Lilly And Company Traitement de pathologies musculosquelettiques par le polypeptide lp85 et des analogues de celui-ci
WO2001089450A3 (fr) * 2000-05-19 2002-05-02 Lilly Co Eli Traitement de pathologies musculosquelettiques par le polypeptide lp85 et des analogues de celui-ci
EP1483298A2 (fr) * 2002-02-11 2004-12-08 ZymoGenetics, Inc. Materiaux et procedes pour la preparation de facteurs de croissance dimeres
EP1483298A4 (fr) * 2002-02-11 2007-03-14 Zymogenetics Inc Materiaux et procedes pour la preparation de facteurs de croissance dimeres
US7556941B2 (en) 2002-02-11 2009-07-07 Zymogenetics, Inc. Materials and methods for preparing dimeric growth factors

Also Published As

Publication number Publication date
CA2370948C (fr) 2012-07-31
AU4714500A (en) 2000-11-17
CA2370948A1 (fr) 2000-11-09
MXPA01011158A (es) 2004-06-03
JP2002542825A (ja) 2002-12-17
EP1177293A1 (fr) 2002-02-06
WO2000066736B1 (fr) 2000-12-21

Similar Documents

Publication Publication Date Title
US7514238B2 (en) Growth factor homolog zvegf4
US7658920B2 (en) Method of inhibiting the activity of growth factor homolog ZVEGF3
JP5345997B2 (ja) 成長因子相同体ｚｖｅｇｆ３
CA2370948C (fr) Homologue du facteur de croissance zvegf4
US20020081700A1 (en) Snake venom polypeptide zsnk1
MXPA01005749A (en) Growth factor homolog zvegf3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2370948

Country of ref document: CA

Ref country code: CA

Ref document number: 2370948

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011158

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 615760

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 47145/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000928993

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928993

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642